On Tuesday, Emergent Biosolutions Inc (NYSE: EBS) opened lower -5.33% from the last session, before settling in for the closing price of $9.2. Price fluctuations for EBS have ranged from $4.02 to $12.73 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 611.59% at the time writing. With a float of $51.05 million, this company’s outstanding shares have now reached $53.70 million.
Emergent Biosolutions Inc (EBS) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Emergent Biosolutions Inc is 4.31%, while institutional ownership is 74.47%. The most recent insider transaction that took place on Aug 15 ’25, was worth 62,853. In this transaction Director of this company sold 7,086 shares at a rate of $8.87, taking the stock ownership to the 71,799 shares. Before that another transaction happened on Aug 15 ’25, when Company’s Director proposed sale 7,086 for $8.87, making the entire transaction worth $62,853.
Emergent Biosolutions Inc (EBS) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted 1.37 earnings per share (EPS) for the quarter, besting the agreed prediction (set at 0.14) by 1.23. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.21 per share during the current fiscal year.
Emergent Biosolutions Inc (NYSE: EBS) Trading Performance Indicators
Check out the current performance indicators for Emergent Biosolutions Inc (EBS). In the past quarter, the stock posted a quick ratio of 3.00. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.55. Likewise, its price to free cash flow for the trailing twelve months is 3.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.45, a number that is poised to hit 0.00 in the next quarter and is forecasted to reach 0.96 in one year’s time.
Technical Analysis of Emergent Biosolutions Inc (EBS)
Compared to the last year’s volume of 1.25 million, its volume of 1.08 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 48.68%.
During the past 100 days, Emergent Biosolutions Inc’s (EBS) raw stochastic average was set at 83.16%, which indicates a significant increase from 70.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.62 in the past 14 days, which was higher than the 0.42 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.32, while its 200-day Moving Average is $7.51. Nevertheless, the first resistance level for the watch stands at $9.11 in the near term. At $9.50, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.79. If the price goes on to break the first support level at $8.43, it is likely to go to the next support level at $8.14. Now, if the price goes above the second support level, the third support stands at $7.75.
Emergent Biosolutions Inc (NYSE: EBS) Key Stats
There are currently 53,351K shares outstanding in the company with a market cap of 464.69 million. Presently, the company’s annual sales total 1,044 M according to its annual income of -190,600 K. Last quarter, the company’s sales amounted to 140,900 K and its income totaled -12,000 K.
